Non-Small Cell Lung Cancer (NSCLC) — Expanded Access Programs
Overview
Right2Hope maintains a directory of 37 expanded access programs, clinical trials, and compassionate use pathways listed for Non-Small Cell Lung Cancer (NSCLC). Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with non-small cell lung cancer (nsclc) programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 29 programs are currently active or recruiting, with the remaining 8 in other lifecycle stages. Sponsors actively running programs in this area include AstraZeneca, Revolution Medicines, Inc., Bristol-Myers Squibb, Merck Sharp & Dohme LLC, AbbVie, and others.
By recruiting status
Snapshot of where every Non-Small Cell Lung Cancer (NSCLC) program currently sits in its lifecycle.
- Active / Recruiting29
- Inactive8
Top sponsors
Organisations running the most Non-Small Cell Lung Cancer (NSCLC) programs in the directory.
- AstraZeneca5 programs
- Revolution Medicines, Inc.5 programs
- Bristol-Myers Squibb3 programs
- Merck Sharp & Dohme LLC3 programs
- AbbVie1 program
- Agenus Inc.1 program
- Amgen1 program
- Astellas Pharma Global Development, Inc.1 program
- Duke University1 program
- EMD Serono Research & Development Institute, Inc.1 program
Non-Small Cell Lung Cancer (NSCLC) programs (37)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on IMM-1-104 for Patients with Previously Treated Advanced or Metastatic Solid Tumors with RAS Mutation — Immuneering Corporation
- Study Comparing Sotorasib with Chemotherapy to Pembrolizumab with Chemotherapy for Advanced Non-Small Cell Lung Cancer — Amgen
- Study on MT-4561 for Patients with Advanced Solid Tumors — Mitsubishi Tanabe Pharma America Inc.
- Comparing Setidegrasib (ASP3082) and Docetaxel for Non-small Cell Lung Cancer with KRAS G12D Mutation — Astellas Pharma Global Development, Inc.
- Study Comparing Pumitamig and Durvalumab After Chemoradiation in Patients with Unremovable Stage III Non-small Cell Lung Cancer — Bristol-Myers Squibb
- Study Comparing Pumitamig and Pembrolizumab for Untreated Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels — Bristol-Myers Squibb
- Study on the Safety and Effectiveness of BMS-986523 Alone and with Other Cancer Treatments for Advanced Solid Tumors — Bristol-Myers Squibb
- Program to Access Botensilimab and Balstilimab Before Official Approval — Agenus Inc.
- Study on GEN1042 Safety and Anti-Tumor Effects in Patients with Advanced Solid Tumors — Genmab
- PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung — Duke University
- Study on Pembrolizumab for Advanced Non-Small Cell Lung Cancer (NSCLC) with Performance Status 2-3 — Icahn School of Medicine at Mount Sinai
- Study on Immunotherapy Combinations for Advanced Non-Small Cell Lung Cancer (NSCLC) — Servier Bio-Innovation LLC
- Phase 3 Study of Taletrectinib vs Placebo as an Additional Treatment in ROS1 Positive Non-Small Cell Lung Cancer (NSCLC) — Nuvation Bio Inc.
- Phase III Study Comparing Datopotamab Deruxtecan and Docetaxel for Advanced TROP2-positive Non-squamous Lung Cancer — AstraZeneca
- Study on Sacituzumab Tirumotecan and Pembrolizumab Combination Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer with High PD-L1 Levels — Merck Sharp & Dohme LLC
- Study Comparing Sacituzumab Tirumotecan to Chemotherapy in Previously Treated Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer with EGFR Mutations or Other Genetic Changes — Merck Sharp & Dohme LLC
- Study Comparing Sacituzumab Tirumotecan with Pemetrexed and Carboplatin for Advanced Non-Small Cell Lung Cancer with EGFR Mutation — Merck Sharp & Dohme LLC
- Study on Anti-CEACAM5 ADC M9140 for Advanced Solid Tumors (PROCEADE PanTumor) — EMD Serono Research & Development Institute, Inc.
- Study on Durvalumab and Tremelimumab with Chemotherapy or Chemotherapy Alone for Lung Cancer Patients (POSEIDON) — AstraZeneca
- Study on Durvalumab with Olaparib or Alone After Initial Treatment in Lung Cancer Patients (ORION) — AstraZeneca
- Study on Elironrasib and Daraxonrasib for Advanced KRAS G12C Mutant Solid Tumors — Revolution Medicines, Inc.
- Study on First-In-Human Use of STX-241 for Advanced or Metastatic Lung Cancer Resistant to EGFR Treatments — Pierre Fabre Medicament
- Study on Osimertinib and Targeted Radiation for EGFR Mutant Non-Small Cell Lung Cancer — University of Texas Southwestern Medical Center
- Study on Pembrolizumab, Pemetrexed, and Platinum Chemotherapy with or without Zoldonrasib for First-Line Treatment in Advanced Non-Squamous Lung Cancer with RAS G12D Mutation — Revolution Medicines, Inc.
- Study on New RAS(ON) Inhibitor Combinations for Patients with Advanced RAS-Mutated Non-Small Cell Lung Cancer — Revolution Medicines, Inc.
- Study on RAS(ON) Inhibitors with Ivonescimab for Patients with Solid Tumors — Revolution Medicines, Inc.
- Study on RMC-6236 for Patients with Advanced Solid Tumors with Specific RAS Mutations — Revolution Medicines, Inc.
- Study on the Immune Response of MUC1 Peptide Vaccine for Non-Small Cell Lung Cancer — Olivera Finn
- Study on GTAEXS617 for Adults with Advanced Solid Tumors — Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- Study on AZD0022 for Treating Tumors with KRASG12D Mutation in Adults — AstraZeneca
- Study on TAK-186 (MVC-101) for Adults with Advanced or Metastatic Cancer — Takeda
- Study on Tiragolumab and Atezolizumab Compared to Placebo and Atezolizumab in Patients with Completely Removed Non-Small Cell Lung Cancer After Chemotherapy — Hoffmann-La Roche
- A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations — AstraZeneca
- Study on the Safety and Effects of IDE574 Therapy in Adults with Advanced Solid Tumors — IDEAYA Biosciences
- Expanded Access to Telisotuzumab Vedotin — AbbVie
- Access Programs for LDK378, Ceritinib — Novartis Pharmaceuticals
- Study on Inhaled Azacytidine with Chemotherapy and Immunotherapy for Treating Early-Stage Non-Small Cell Lung Cancer — National Cancer Institute (NCI)
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Non-Small Cell Lung Cancer (NSCLC) to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.